Fusion-competent vaccines: Broad neutralization of primary isolates of HIV

Rachel A. LaCasse, Kathryn E. Follis, Meg Trahey, John D. Scarborough, Dan R. Littman, Jack H. Nunberg

Research output: Contribution to journalArticlepeer-review

Abstract

Current recombinant human immunodeficiency virus (HIV) gp 120 protein vaccine candidates are unable to elicit antibodies capable of neutralizing infectivity of primary isolates from patients. Here, 'fusion-competent' HIV vaccine immunogens were generated that capture the transient envelope-CD4- coreceptor structures that arise during HIV binding and fusion. In a transgenic mouse immunization model, these formaldehyde-fixed whole-cell vaccines elicited antibodies capable of neutralizing infectivity of 23 of 24 primary HIV isolates from diverse geographic locations and genetic clades A to E. Development of these fusion-dependent immunogens may lead to a broadly effective HIV vaccine.

Original languageEnglish
Pages (from-to)357-362
Number of pages6
JournalScience
Volume283
Issue number5400
DOIs
StatePublished - Jan 15 1999

Fingerprint

Dive into the research topics of 'Fusion-competent vaccines: Broad neutralization of primary isolates of HIV'. Together they form a unique fingerprint.

Cite this